Dear Editor, OnabotulinumtoxinA (BOTOX) has been approved for prophylaxis in chronic migraine (CM) since 2010 1 based on the findings of the Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) trial. 2 The duration of BOTOX efficacy is known to be 3 months, but prolonged efficacy (>3 months) after a single cycle of BOTOX has not been evaluated thoroughly. Moreover, the efficacy and adverse effects of BOTOX have rarely been documented in Koreans. We report subjective headache improvements in Korean subjects with CM who received a single cycle of BOTOX.
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tion and is probably due to its effects on central antinociception. 4 Applying the PREEMPT protocol in Asian migraineurs can reportedly cause cosmetic problems such as upward deviation of the lateral part of the eyebrows or transverse wrinkles between the eyes. Because the forehead tends to be broader in Asians than in Caucasians, 5 broader injections into the forehead may be considered than those suggested by the PRE-EMPT protocol. 2 This study retrospectively observed subjective headache improvements after BOTOX treatment. However, the retrospective design means that we cannot rule out other possible confounders that can affect headache improvement. The improvement was evaluated by subjective statements from the patients, not by headache diaries. Since there was no control group, a placebo effect in the headache improvement cannot be ruled out.
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